Risk factors for infection in patients with remitted rheumatic diseases treated with glucocorticoids

Yoshinori Matsumoto, Kenei Sada, Mariko Narazaki, Noriko Toyota, Ryutaro Yamanaka, Koichi Sugiyama, Hiroshi Wakabayashi, Tomoko Kawabata, Fumio Otsuka, Hirofumi Makino

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)


It is well known that infection is one of the major causes of morbidity and mortality in rheumatic disease patients treated with high-dose glucocorticoids, especially in the early phase after achievement of disease remission. The aim of this study was to identify the risk factors for infection, with a focus on the dose of glucocorticoids administered, following the achievement of disease remission in rheumatic diseases patients. We retrospectively analyzed the medical records of rheumatic disease patients who had been treated with glucocorticoids. The primary endpoint was the incidence rate of infection during a period from 1 to 2 months after the commencement of treatment. From April 2006 to March 2010, 19 of 92 patients suffered from infection during the observation period. Age ≥ 65 yrs, presence of interstitial pneumonia, diagnosis of systemic vasculitis and serum creatinine levels ≥ 2.0mg/dl were found to be univariate predictors for infection. However, only the presence of interstitial pneumonia was an independent risk factor for infection (HR = 4.50, 95%CI = 1.65 to 14.44) by the Cox proportional hazard model. Even after achievement of clinical remission, careful observation is needed for patients with interstitial pneumonia, more so than for those receiving high-dose glucocorticoids.

Original languageEnglish
Pages (from-to)329-334
Number of pages6
JournalActa medica Okayama
Issue number5
Publication statusPublished - 2011


  • Glucocorticoids
  • Infection
  • Interstitial pneumonia
  • Rheumatic disease
  • Risk factors

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)


Dive into the research topics of 'Risk factors for infection in patients with remitted rheumatic diseases treated with glucocorticoids'. Together they form a unique fingerprint.

Cite this